Graham, Jove http://orcid.org/0000-0002-7881-8588
Novosat, Tonia
Sun, Haiyan
Piper, Brian J.
Boscarino, Joseph A.
Kern, Melissa S.
Hayduk, Vanessa A.
Wright, Eric A.
Beck, Craig
Robinson, Rebecca L.
Casey, Edward
Hall, Jerry
Dorling, Patricia
Funding for this research was provided by:
Pfizer
Article History
Received: 8 February 2022
Accepted: 7 April 2022
First Online: 10 May 2022
Acknowledgments
:
: The study and Rapid Service Fee were sponsored by an institutional research grant from Pfizer, Inc. (New York, NY) and Eli Lilly and Company (Indianapolis, IN).
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
: All authors contributed to the conception and design of the study and interpretation of data, and all authors provided substantial contributions to the final manuscript. JG and HS were directly responsible for the primary analysis of data, and JG as first author was responsible for the initial draft of this manuscript.
: The authors wish to thank Matt Gass and Celia Gray for their help with assembling the study dataset and thank Pfizer and Eli Lilly and Company for the institutional grant that funded this work.
: Patricia Dorling, Craig Beck, and Edward Casey are employees of Pfizer and have stock options. Rebecca Robinson and Jerry Hall are employees and stockholders at Eli Lilly and Company. Jove Graham, Brian Piper, Joseph Boscarino, Melissa Kern, Vanessa Hayduk, and Eric Wright are employees of Geisinger, which received institutional funding from Pfizer and Eli Lilly and Company for the study. During the study period, Tonia Novosat and Haiyan Sun were employees of Geisinger, which received institutional funding from Pfizer and Eli Lilly and Company for the study.
: This study was performed in line with the principles of the Helsinki Declaration of 1964 and its later amendments. It was reviewed and approved (IRB #2019-1033) by Geisinger's Institutional Review Board (IRB) as meeting the criteria for exemption as defined in the U. S. Department of Health and Human Services Regulations for the Protection of Human Subjects [(45 CFR 46.104)]. The specific exemption category under 45 CFR 46.104 was category 4, secondary research for which consent was not required for a retrospective study.
: The datasets generated and analyzed during the current study are not publicly available due to patient privacy concerns and ownership by Geisinger but additional deidentified information could be made available from the corresponding author on reasonable request.
: This manuscript is based on work that was accepted for poster presentations at the American College of Rheumatology (ACR) Convergence 2021 Annual Meeting held virtually from November 1–10, 2021, the Osteoarthritis Research Society International (OARSI) 2021 World Congress held virtually from April 29-May 3, 2021, and the European Congress of Rheumatology (EULAR) Congress held virtually from June 2–5, 2021.